Arovella Therapeutics Limited
ALA
Rank in Stocks
#23376
Arovella Therapeutics Limited, an Australian biotechnology firm, is dedicated... Arovella Therapeutics Limited, an Australian biotechnology firm, is dedicated to developing therapeutic solutions for oncology and central nervous system afflictions, operating both domestically and internationally. Its pipeline features several key assets, including ZolpiMist, an oral spray formulation of zolpidem tartrate for the treatment of short-term insomnia, commercially known by brands such as Ambien or Stilnox. The company is also advancing an invariant natural killer T (iNKT) cell therapy platform specifically designed to target blood cancers. Furthermore, Arovella employs OroMist, an oro-mucosal technology enabling the delivery of various drug classes through absorption in the oral cavity via the cheeks, gums, tongue, or mouth floor, and is developing Anagrelide for cancer treatment. Beyond these, the company is engaged in creating oral sprays to address conditions like migraine headaches, motion sickness, and drug-resistant epilepsy. Arovella maintains a research collaboration agreement with Imperial College London. Established in 1999 and based in Osborne Park, Australia, the company was formerly known as Suda Pharmaceuticals Ltd before rebranding to Arovella Therapeutics Limited in October 2021.
Share Price
$0.03530169
Last synced: 2026-11-10
Market Cap
$42.67M
Change (1 day)
2.00%
Change (1 year)
-41.28%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Arovella Therapeutics Limited (ALA)
Category
Healthcare
Operating Margin for Arovella Therapeutics Limited (ALA)
Operating Margin as of November 2026 TTM: 0.00%
According to Arovella Therapeutics Limited's latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of -8,237.35%.
Operating Margin history for Arovella Therapeutics Limited from 2001 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | -100.00% |
| 2025 | -8,237.35% | -87.05% |
| 2024 | -63,595.65% | 2,566.46% |
| 2023 | -2,385.02% | -7.08% |
| 2022 | -2,566.71% | 120.57% |
| 2021 | -1,163.67% | 55.90% |
| 2020 | -746.44% | 292.53% |
| 2019 | -190.16% | -86.59% |
| 2018 | -1,418.55% | 5,569.66% |
| 2017 | -25.02% | -48.18% |
| 2016 | -48.28% | -30.11% |
| 2015 | -69.08% | 193.21% |
| 2014 | -23.56% | -44.75% |
| 2013 | -42.64% | 4.38% |
| 2012 | -40.85% | -56.89% |
| 2011 | -94.75% | -99.34% |
| 2010 | -14,358.16% | 17.10% |
| 2009 | -12,261.79% | 49,805.54% |
| 2008 | -24.57% | 63.69% |
| 2007 | -15.01% | 18,662.50% |
| 2006 | -0.08% | -99.63% |
| 2005 | -21.34% | 15.73% |
| 2004 | -18.44% | -97.51% |
| 2003 | -741.34% | 0.00% |
| 2002 | 0.00% | 0.00% |
| 2001 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Arovella Therapeutics Limited's operating margin
What was Arovella Therapeutics Limited's operating margin in 2025?
In 2025, Arovella Therapeutics Limited's operating margin was -8,237.35%, compared with -63,595.65% in 2024.
How has Arovella Therapeutics Limited's operating margin changed since 2020?
From 2020 to 2025, Arovella Therapeutics Limited's operating margin was highest in 2020 (-746.44%) and lowest in 2024 (-63,595.65%).
How does Arovella Therapeutics Limited's operating margin compare with similar companies?
Arovella Therapeutics Limited's operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.